Delivery Order HHSN268201200010I-HHSN26800001

This federal contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genomic research products and services. The $299,952 firm-fixed price contract is for "GENETIC ANALYSIS OF CTCS AT THE SINGLE-CELL LEVEL" and does not have a set-aside designation. Cellecta specializes in providing advanced genomic technologies, including CRISPR, RNAi, and other tools, to support biomedical research...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $20,130.00 firm-fixed-price purchase order to Cellecta, Inc. (doing business as Cellecta Inc.), a for-profit organization and manufacturer of goods. The award is for the delivery of a human genome-wide CRISPR-Cas9 dual-single guide RNA (sgRNA) library (virus). This contract is not set aside for any type of small business. Cellecta has previously provided a...

This is a definitive contract awarded by the National Cancer Institute, a civilian agency of the U.S. government, to Cellerant Therapeutics, Inc. for the development of IL1RAP antibodies targeting acute myeloid leukemia (AML) cancer stem cells. The contract has a firm fixed price of $223,524.00 and a completion date of August 11, 2015. This contract is not designated as a set-aside. The purpose of the contract is to support the development of these antibodies, which may contribute to the...

The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $16,000.00 firm fixed price purchase order to Cellecta, Inc. for the delivery of a "HUMAN GENOME-WIDE CRISPRI DUAL-SGRNA LIBRARY (VIRUS)". This order, which does not have a set-aside designation, will be completed by September 7, 2022. Cellecta, Inc. is a for-profit organization that specializes in providing genetic screening services, including...

This $24,000 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Cellecta, Inc. Cellecta is a for-profit manufacturer of specialty genetic screening products and services used in medical research and drug discovery. The contract does not have a small business set-aside designation. Cellecta frequently partners as the prime contractor to provide CRISPR, RNAi, and other genomic...

This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Cellecta, Inc., a for-profit manufacturer of genetic research tools and services. The $13,500.00 contract is for the delivery of Cellecta's proprietary lentiviral packaging products to support biomedical research. The contract does not have a small business set-aside designation. Cellecta has consistently secured federal contracts and grants, primarily from the National...

This is a $26,780.00 firm fixed price purchase order awarded to Cellgenix USA, a division of Cellgenix GmbH, by the National Institutes of Health (NIH) Clinical Center. The contract is for the provision of various cytokines, growth factors, and other pharmaceuticals to support cell and gene therapy research and development. No set aside designation was used for this award. Cellgenix USA has previously held other prime federal contracts with the NIH Clinical Center and National Institute of...

This is a $198,641 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Nanocellect Biomedical Inc., a for-profit biotechnology company. The contract is for the development of a "CTC Label and Capture by Lab-on-a-Chip Flow-Cytometry" solution, which aligns with the NCI's research interests. Nanocellect Biomedical is an innovative provider of automated cell analysis, sorting, and dispensing equipment and services, with a strong...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lisata Therapeutics Inc. (doing business as Caladrius Biosciences) for the development of novel therapeutic agents that target cancer stem cells. The definitive, firm fixed-price contract has a total ceiling value of $4,378,214.00 and a completion date of June 20, 2018. The contract was set aside for small businesses.</p>

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...